There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Background Treatment with natalizumab once every 4 weeks is approved for patients with
relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal …

Experimental autoimmune encephalomyelitis (EAE) is the most commonly used
experimental model for the human inflammatory demyelinating disease, multiple sclerosis …

Importance With multiple and increasingly effective therapies for relapsing forms of multiple
sclerosis (MS), disease-free status or no evidence of disease activity (NEDA) has become a …

Background:'No evidence of disease activity'(NEDA), defined as absence of magnetic
resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and …

Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …

Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …

Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …

The management of multiple sclerosis is becoming increasingly complex with the
emergence of new and more effective disease-modifying therapies (DMT). We propose a …